Plant-based COVID-19 vaccine demonstrates 70% efficacy

The vaccine was developed by researchers at Canadian biotechnology company Medicago, and it contains coronavirus-like particles (CoVLP) produced in plants, which are combined with an adjuvant (ASO3) that helps vaccines work better.

The jab, Covifenz, was found to be highly effective in preventing disease caused by five different viral strains or variants in a human trial conducted by researchers. The study was published in the journal New England Journal of Medicine (NEJM).

read more